Advancing First-in-Class Therapeutics

from

Our Biology-First AI Platform

Auransa's AI-Discovered Cancer Drug AU409 Shows Promising Clinical Activity — Hear from the Lead Clinical Investigator

WATCH NOW >>

Auransa's AI-Discovered Cancer Drug AU409 Shows Promising Clinical Activity — Hear from the Lead Clinical Investigator WATCH NOW >>

MEET AURANSA

We are a clinical stage, AI-native biopharma with a proprietary AI platform that harnesses available human disease data to discover novel therapeutics and raise the standard of cancer care.

From AI Discovery to Clinical Development

Our biology-first AI platform has delivered AU409, a novel, first-in-class cancer drug now in clinical trials, demonstrating the potential to translate human disease biology into meaningful therapeutic advances.

SEE OUR PLATFORM >>

AU409

Auransa's AI-discovered, first-in-class oral cancer drug AU409 is being evaluated in a Phase 1 clinical trial, demonstrating encouraging antitumor activity, including a durable complete response* in a patient with advanced hepatocellular carcinoma.

*Complete response by modified RECIST (mRECIST), as reported by the clinical investigator; partial response by RECIST 1.1.

SEE OUR PIPELINE >>

“As an early pioneer in genomics technology, first at Rosetta and later at Merck, I’ve long been a champion of the integration of data science into biological discovery. I am most excited by the next chapter; Auransa and the intersection of AI, biology, massive data, and precision medicine.” 

Pek Lum, Co-Founder and CEO, Auransa